Does Aetna (CVS Health) Cover Repatha (Evolocumab)?

How Aetna Categorizes Repatha on Its Formulary

Aetna places evolocumab on a specialty drug tier, typically Tier 4 or Tier 5, on its commercial PPO, HMO, and Aetna CVS Health exchange plans. That tier designation means cost-sharing is highest in the formulary structure, often 25 to 33 percent coinsurance after the deductible, rather than a flat copay. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Aetna's drug policy follows the clinical logic behind the FDA label closely. Because evolocumab is a biologic injectable that inhibits PCSK9, it occupies a distinct drug class from statins and ezetimibe. Aetna's published clinical policy bulletins treat PCSK9 inhibitors as medically necessary only when lower-cost agents have been tried first, which is the practical definition of step therapy.

Formulary placement also varies by plan year. Patients on Aetna Medicare Advantage plans face separate Part D formulary rules, and coverage may differ from commercial plans even within the same geographic market. Checking the specific plan's Evidence of Coverage document or calling the Aetna pharmacy benefits line (the number on the back of the member ID card) is the fastest way to confirm tier placement for the current plan year.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states that PCSK9 inhibitors are reasonable for patients with clinical ASCVD who are on maximally tolerated statin therapy and still have LDL-C at or above 70 mg/dL [2]. That guideline language is directly reflected in Aetna's PA criteria, making guideline compliance the clearest path to approval.

Prior Authorization Criteria Aetna Applies to Repatha

Aetna rates its own prior authorization process for Repatha as moderate-to-high difficulty. The core clinical criteria a prescriber must document include: a confirmed diagnosis of HeFH, HoFH, or established clinical ASCVD; documentation that the patient has tried and either failed or cannot tolerate at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg); and a recent LDL-C laboratory value demonstrating insufficient response [3].

The PA form also typically asks for the patient's current LDL-C level and the LDL-C goal the prescribing clinician is targeting. For ASCVD patients, the 2022 ACC Expert Consensus Decision Pathway recommends an LDL-C goal below 70 mg/dL, and for very-high-risk patients a goal below 55 mg/dL [4]. Submitting a PA that explicitly references those thresholds, paired with a current lipid panel, strengthens the case.

For homozygous FH specifically, Aetna generally waives the step therapy statin requirement because HoFH patients have severely limited or absent LDL receptor activity and statins produce minimal LDL-C lowering in that population. The prescriber should document the HoFH diagnosis clearly, ideally with genetic confirmation or clinical criteria from the European Atherosclerosis Society consensus [5].

Statin intolerance is an accepted pathway but requires documentation. Aetna typically expects records showing at least two different statins at any dose caused myopathy, rhabdomyolysis, or other adverse effects that forced discontinuation. A letter from the prescriber alone is usually insufficient. Lab values (elevated CK, hepatic enzymes) and clinical notes from the time of the adverse event carry more weight.

In FOURIER (N=27,564), patients randomized to evolocumab 140 mg every two weeks or 420 mg monthly achieved a 59% reduction in LDL-C from baseline at 48 weeks (mean LDL-C 30 mg/dL vs. 92 mg/dL on placebo, P<0.001), and the composite MACE endpoint was reduced by 15% over a median 2.2 years [6]. Quoting those numbers in the PA letter, alongside the patient's own LDL-C, provides objective clinical grounding.

Processing time for Aetna PCSK9 inhibitor PAs is typically 3 to 5 business days for standard review or 24 to 72 hours for urgent review when the prescriber documents clinical urgency. Submitting an incomplete PA is the single most common reason for denial, so confirming all required fields with the prescribing office before submission saves significant time.

Step Therapy Requirements Before Repatha Is Approved

Step therapy is the most common obstacle. On most Aetna commercial plans, a patient must demonstrate an adequate trial of at least one high-intensity statin plus ezetimibe 10 mg before evolocumab will be covered. The duration Aetna requires for that combination trial varies by plan but is commonly 90 days at therapeutic doses [7].

Ezetimibe alone adds roughly an 18 to 20% LDL-C reduction beyond statin therapy. The SHARP trial (N=9,270) demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% compared to placebo over 4.9 years [8]. That evidence base is exactly why Aetna and most payers position ezetimibe as a required step before moving to a PCSK9 inhibitor.

Prescribers can bypass the step therapy requirement under several conditions. These include: a documented history of statin-induced myopathy or rhabdomyolysis; a confirmed HoFH diagnosis; a prior Aetna approval for a PCSK9 inhibitor that lapsed only because of a plan year change; or a clinical exception request supported by a specialist (cardiologist or lipidologist) explaining why step therapy would be medically harmful for the specific patient.

Several states have enacted step therapy protection laws requiring insurers to grant exceptions within defined timeframes. As of 2024, at least 30 states have some form of step therapy override legislation, and Aetna must comply with state-specific requirements when they are stricter than Aetna's internal policy [9]. A prescriber or patient advocate should check their state's insurance commissioner website to determine whether that protection applies.

What Happens When Aetna Denies Repatha Coverage

A denial is not the end of the process. Aetna's denial letters must, by federal law under the ACA, explain the specific clinical reason for denial and describe the appeal rights. Reading that reason carefully is the first step because the appeal strategy should directly rebut the stated rationale [10].

First-level internal appeal. The prescriber or patient submits a written appeal within 180 days of the denial (the plan's denial letter will state the exact deadline). The appeal packet should include: updated clinical notes, recent LDL-C values, documentation of prior statin and ezetimibe trials, and a physician attestation letter. Peer-reviewed literature, such as the FOURIER trial data, can be attached [6]. Aetna is required to decide first-level appeals within 30 days for non-urgent cases or 72 hours for urgent ones.

Second-level internal appeal. If the first-level appeal fails, a second internal review by a different Aetna medical reviewer is available. This review often includes a peer-to-peer call between the Aetna medical director and the prescribing physician. These peer-to-peer conversations have a meaningfully higher overturn rate than written appeals alone, so requesting one proactively at the first denial stage is worth considering.

External independent review. If both internal levels fail, federal and state law entitles the patient to an independent external review by an organization not affiliated with Aetna. External reviewers overturn insurer denials at rates that vary by condition; for specialty drugs with strong guideline support, overturn rates can exceed 40% in some analyses [11]. The external reviewer's decision is binding on Aetna.

Expedited appeal. When a treating cardiologist or lipidologist documents that delay poses serious risk to the patient's health, an expedited appeal compresses the standard timeline to 72 hours or less.

The HealthRX clinical team organizes the Aetna Repatha appeal into a four-document packet that consistently addresses the four most common denial reasons: incomplete step therapy documentation, missing LDL-C lab values dated within 90 days, absent specialist attestation, and failure to cite the applicable state step therapy exception law. Assembling all four before submitting the first-level appeal avoids the most frequent procedural rejections.

LDL-C Reductions That Support Medical Necessity Claims

The clinical evidence for evolocumab is one of the strongest in cardiovascular pharmacology. FOURIER enrolled 27,564 patients with established ASCVD already on optimized statin therapy. Over a median 2.2 years, evolocumab reduced LDL-C by 59% (from a mean 92 mg/dL to 30 mg/dL) and cut the composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [6]. MI was reduced by 27% and stroke by 21%.

The GLAGOV trial (N=968) demonstrated that evolocumab added to statin therapy produced regression of coronary atherosclerosis as measured by intravascular ultrasound after 76 weeks: a mean percent atheroma volume change of -0.95% vs. +0.05% on placebo (P<0.001) [12]. That trial provides biological plausibility, and its data can be cited in PA letters or appeals to demonstrate disease-modifying, not just lipid-modifying, benefit.

For familial hypercholesterolemia specifically, the RUTHERFORD-2 trial (N=329) showed that evolocumab 140 mg every two weeks reduced LDL-C by 59.2% from baseline in HeFH patients already on statin therapy, with 81.8% of patients reaching an LDL-C below 100 mg/dL [13]. Patients seeking Aetna coverage for HeFH can cite RUTHERFORD-2 alongside their own LDL-C values to demonstrate the treatment's expected benefit in their specific indication.

The ACC/AHA 2019 Primary Prevention Guideline notes that for patients with LDL-C at or above 190 mg/dL (consistent with familial hypercholesterolemia), statin therapy is recommended first, but a PCSK9 inhibitor may be considered if LDL-C remains substantially elevated despite maximally tolerated statin and ezetimibe [14]. That guideline language provides a second independent textual basis for PA approval beyond the 2018 cholesterol guideline.

Cost Without Insurance and Manufacturer Assistance Programs

Without insurance, evolocumab costs approximately $580 per month at most U.S. pharmacies, consistent with the list price Amgen publishes. That figure represents an annual spend of roughly $6,960 before any discounts.

Amgen offers the Repatha SupportPlus program. Commercially insured patients who meet income requirements may pay as little as $5 per month through the manufacturer's savings card. The savings card is explicitly not available to patients enrolled in Medicare, Medicaid, or any other government-funded health program; using it in those programs violates federal anti-kickback rules [15].

For Medicare beneficiaries, Amgen offers a separate patient assistance program (Amgen Safety Net Foundation) for those who meet income thresholds, generally at or below 400% of the federal poverty level. Applications are processed through the prescriber's office or directly at Amgen's patient support line.

Specialty pharmacy copay accumulator programs used by some Aetna plans may prevent manufacturer coupon payments from counting toward the patient's deductible or out-of-pocket maximum. Patients should ask Aetna specifically whether their plan uses a copay accumulator or copay maximizer arrangement, because that distinction changes the true out-of-pocket cost significantly over a plan year.

The average net price Amgen receives after rebates, according to Amgen's own financial disclosures cited in pharmacy benefit analyses, is substantially below list price, but individual patient cost-sharing is still calculated on list price in many plan designs, making the savings card critical for commercially insured patients [16].

Aetna Medicare Advantage and Part D Coverage for Repatha

Medicare Advantage plans administered by Aetna follow Part D formulary rules established by CMS. Repatha may appear on the Part D formulary at the specialty tier, but coverage and PA criteria differ from Aetna commercial plans. CMS requires that Medicare drug plans cover at least two drugs in each therapeutic category, but PCSK9 inhibitors are classified in a category where both evolocumab and alirocumab (Praluent) may be covered, or plans may restrict to one [17].

Part D plans are prohibited from requiring step therapy for drugs that CMS classifies as "protected class" medications, but PCSK9 inhibitors do not currently fall into a CMS protected class. That means step therapy and PA remain permissible under Medicare rules. Patients on Aetna Medicare Advantage should request the specific plan's Part D formulary document and compare it against the commercial formulary, as criteria differ materially.

The Medicare Extra Help (Low Income Subsidy) program can reduce Part D cost-sharing for qualifying beneficiaries, including the specialty tier costs that would otherwise apply to evolocumab. Income and asset thresholds for Extra Help are set annually by CMS [18].

Comparing Evolocumab to Alirocumab for Coverage Strategy

Alirocumab (Praluent, made by Sanofi/Regeneron) is the other approved PCSK9 inhibitor in the U.S. market. Some Aetna plans prefer alirocumab on formulary in a given plan year, meaning alirocumab would carry lower cost-sharing and potentially less PA friction. Inclisiran (Leqvio), a small interfering RNA that reduces PCSK9 expression rather than blocking the protein, received FDA approval in December 2021 and is beginning to appear on commercial formularies [19].

If a patient is denied evolocumab specifically because alirocumab is the preferred PCSK9 inhibitor on the Aetna plan, switching to alirocumab rather than appealing may be the faster clinical path, assuming the patient's prescriber and specialty pharmacy can accommodate the switch. The LDL-C reductions between the two agents are comparable: the ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced MACE by 15% over a median 2.8 years in post-acute coronary syndrome patients [20].

However, if a patient has already been stabilized on evolocumab and is achieving goal LDL-C, a forced formulary switch carries clinical and logistical risks. In that situation, documenting therapeutic response to evolocumab specifically (LDL-C values on therapy, adherence data from specialty pharmacy) and requesting a formulary exception on continuity-of-care grounds is a reasonable appeal strategy.

Practical Steps for Prescribers Submitting a Repatha PA to Aetna

The prescriber's office initiates the PA through Aetna's provider portal, by phone to Aetna's pharmacy management line, or through a specialty pharmacy that handles PA submission as a service. Amgen's SupportPlus program includes PA support staff who can assist with submission and track the request.

Required documentation almost always includes:

1. Office visit notes confirming the diagnosis (ICD-10 codes: E78.01 for HeFH, E78.02 for HoFH, I25.10 for chronic ischemic heart disease, I70.x for atherosclerosis).
2. A lipid panel dated within the past 90 days showing current LDL-C.
3. Pharmacy records or prescribing history confirming the statin and ezetimibe trials with dates and doses.
4. Any documentation of statin intolerance, including lab values if myopathy was the reason for discontinuation.
5. A clinical rationale letter from the prescribing cardiologist or lipidologist.

The Endocrine Society's 2017 clinical practice guideline on familial hypercholesterolemia states: "PCSK9 inhibitors are recommended for patients with FH who are not at their LDL-C goal on maximally tolerated lipid-lowering drug therapy" [21]. Quoting that recommendation by name and date in the PA letter adds a second authoritative guideline source beyond ACC/AHA.

Aetna's standard PA approval period for PCSK9 inhibitors is typically 12 months, after which re-authorization requires updated LDL-C values confirming continued clinical response. A re-authorization is generally easier than the initial PA, but it must be initiated before the prior authorization expires to avoid a gap in coverage.

For patients whose LDL-C has reached goal on evolocumab, re-authorization should document that the goal was reached because of evolocumab, not despite it, meaning the prescriber should note what the LDL-C was before starting the drug and what it is now, demonstrating the agent's individual contribution to the patient's lipid control.